Pacific Edge (ASX:PEB) Growth Rank: 8 (As of Aug. 14, 2026) — 60% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PEB Pacific Edge Ltd ASX:PEB
32 GF Score
Price A$0.22
GF Value A$0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pacific Edge Growth Rank?

Pacific Edge ASX:PEB 32 Growth Rank is 8 as of Aug. 14, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates ASX:PEB with a GF Score™ of 32/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Pacific Edge has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ASX:PEB vs TMO, DHR, IDXX: Growth Rank Comparison

For the Diagnostics & Research subindustry, Pacific Edge's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Edge Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Growth Rank distribution charts can be found below:

* The bar in red indicates where Pacific Edge's Growth Rank falls into.


ASX:PEB
32GF Score
Pacific Edge Ltd ASX:PEB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Pacific Edge (ASX:PEB) has a Growth Rank of 8 as of Aug. 14, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Pacific Edge and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, Pacific Edge's Growth Rank has ranged from 3.00 to 10.00.
Is Pacific Edge's Growth Rank too high?
Pacific Edge's current Growth Rank of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Pacific Edge has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Growth Rank compare to TMO and DHR?
Pacific Edge's Growth Rank of 8 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Pacific Edge's own Growth Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Pacific Edge and its competitors. Pacific Edge's current Growth Rank is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.22 — trading 330% above its estimated fair value. The current Growth Rank is 8, which is 60% above median its 10-year median of 5.00. Pacific Edge's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Growth Rank is 8 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.22 is trading 330% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • Growth Rank: 8 (60% above median its 10-year median of 5.00)
  • GF Value™: A$0.05 vs. price of A$0.22 (330% above fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
32GF Score

Get the complete analysis for ASX:PEB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.22
Price
A$0.05
GF Value